Navigation Links
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
Date:10/28/2008

studies suggest that Valortim has the potential to provide significant protection against anthrax infection when administered prophylactically post-exposure (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident).

About Anthrax

According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and intestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics. Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products. However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious d
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA ... transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection against ... operator control device that will increase healthcare worker safety and reduce financial costs. ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty from ... first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members ... course combines students from both universities and is taught on both continents. , ...
(Date:6/30/2015)... -- NASA astronaut Kjell Lindgren , who is making final ... to the International Space Station , will be available ... Tuesday, July 7. Lindgren will participate from the ... . The interviews will be preceded at 7:30 a.m. ... To schedule an interview, media must contact ...
(Date:6/30/2015)... Francisco, CA (PRWEB) , ... June 30, 2015 ... ... FMT Patients , Study will provide new insights on mechanics of fecal microbiota ... a new partnership to study the microbiome of patients undergoing fecal microbiota transplantation ...
Breaking Biology Technology:Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... WOBURN, Mass., Nov. 26 Covaris Incorporated today,announced that ... shipment,of its 500th instrument unit and continued another successful ... Covaris is both,strengthening its sales and marketing organization as ... , The Covaris ...
... TOKYO and CAMBRIDGE, England, November 26 Sosei,Group Corporation ... that it has out-licensed its IP and Know How,relating ... ("Treague"), a,Cambridge, UK based pharma company, for the treatment ... Mefloquine is a highly efficacious anti-malarial drug that ...
... ANDS ) announced today that it will present at ... 3, 2008 at 9:30 a.m. EST (6:30 a.m. PST) at the ... Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will ... ANA598 and ANA773 in hepatitis C and ANA773 in cancer. , ...
Cached Biology Technology:Covaris Installed Instrument Base Reaches 500 Units 2Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria 2Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 ... Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt Laborkosten ... Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die forensische ... Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte Lösung ...
(Date:6/16/2015)... 2015  With the increasing number and severity of ... concern. The recent compromise of Federal employee data ... authentication within government agencies. HYPR Corp. announced ... (OTP) authenticator, has been submitted for testing and approval ... validation for tamper proofing. The proliferation ...
(Date:6/15/2015)... Conn. , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces that ... be showcased to media at Digital Experience! @ NYC June ... summer showcase of the latest innovation in technology to over ... will be held at the Metropolitan Pavilion in ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... of a mathematical model, suggest that international cooperation to ... deal with an emerging pandemic. , 'Bird flu'(avian H5N1 ... because it rarely passes between people. If it does ... develop a vaccine effective against the new virus. Public ...
... normally suppress tumor growth. Now, for the first time, MIT ... mice can cause tumors to shrink or disappear. , ... is a promising target for human cancer drugs. , ... human tumors in which this pathway is blocked, they may ...
... researchers have identified a cellular protein that interferes with ... help scientists develop new drugs to fight the virus. ... “p21-activated kinase 1?(PAK1), was discovered by scientists at the ... describe their findings in an article in the current ...
Cached Biology News:Reactivated gene shrinks tumors 2Reactivated gene shrinks tumors 3Protein found that slows hepatitis C growth in liver cells 2